🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07033754
Starting soon

A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infection

NCT07033754 · tracked via the Priya Life Science India tracker
Sponsor
Vedic Lifesciences Pvt. Ltd.
Phase
N/A
Started
2025-06-25
Last updated
2025-06-24

Condition(s) studied

URTI - Viral Upper Respiratory Tract Infection

Investigational drug(s) / intervention(s)

Propionibacterium freudenreichii P.UF1Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia

Propionibacterium freudenreichii P.UF1: one capsule once a day with/beforebreakfast for 120 days

Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia: one capsule once a day with/beforebreakfast for 120 days

Study summary

The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical studydesigned to assess the effects of IP on immune health in teachers prone to URTI. Approximately 179individuals aged between 18 and 50 years will be screened. Considering a screen failure of 20%,approximately 144 individuals will be randomized in a ratio of 1:1 to receive either the active orplacebo. The study will have at least 100 completed participants i.e. 50 participants in each studyarm after accounting for a dropout/withdrawal rate of 30% at the end of the study. The interventionand follow-up duration for all the study participants will be 120 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: 1. Individuals ready to give voluntary, written informed consent to participate in thestudy. 2. Male and female teachers aged between 18 to 50 years' (both values included) withmoderate physical activity level as per International Physical Activity Questionnaire -Short Form (IPAQ - SF). 3. Individuals with body mass index (BMI) between 22 kg per m2 to 32.0 kg per m2 4. High susceptibility to URTIs at least once every three months for last 1 year (at least 4to 6 episodes in a year). 5. Individuals who have active URTI episode at screening defined as "those having a scoreof less than equal to 5 for at least 2 symptoms out of runny nose, plugged nose,sneezing, sore throat, scratchy throat, cough or head congestion on the WURSS-21". 6. Commitment to adhere to routine diet and physical activity. 7. Willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics andfiber supplements, probiotics, Echinacea, fish oil, vitamin E, etc.) at least 1 one monthprior to screening. 8. Willing to discontinue sleep medications at least 1 month prior to screening and duringthe entire study duration. 9. Individuals willing to complete all study-related and clinical study visits as per theprotocol. Exclusion Criteria: 1. Individuals with a history of rhinitis medicamentosa, anatomical nasal obstruction ordeformity, nasal reconstructive surgery, etc 2. Individuals taking prebiotics, probiotics, synbiotics or post-biotics supplements 1 monthprior to screening. 3. Individuals with known sensitivity to the investigational products or any excipients ofthe product. 4. Individuals with any clinically significant abnormalities of the upper respiratory tract(such as stridor, laryngomalacia, etc.). 5. Individuals suffering from lower respiratory tract infection (LRTI) of any origin. 6. Any individual not willing to follow the abstinence from any home-based remedies for common cold such as steam inhalation, decoctions, and vapor rub, etc. 7. Individuals with uncontrolled type 2 diabetes as assessed by fasting blood glucose lessthan equal to 126 mg per dL. 8. Individuals with uncontrolled hypertension on medication and with systolic bloodpressure less than 140 and or diastolic blood pressure less than equal to 90 mmHg. 9. Individuals who are unable to abstain from herbal or dietary supplements for URTI throughout the study period. 10. Vaccination against influenza or swine flu within 90 days prior to screening. 11. Those who have taken or should be taking or are taking antibiotics, antivirals, steroids,nasal decongestants, antihistamines, NSAIDs, or other medications that are expected to alleviate cold symptoms within two weeks prior to screening. 12. History of any significant neurological and psychiatric condition which may affect theparticipation and inference of the study's end points. 13. Participation in other clinical trials in last 90 days prior to screening 14. Individuals with substance abuse problems (within 2 years) defined as: a) Use ofrecreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine, tobaccoor smoking dependence. b) High-risk drinking as defined by consumption of 4 or morealcohol containing beverages on any day or 8 or more alcohol containing beverages perweek for women and 5 or more alcohol-containing beverages on any day or 15 or morealcohol containing beverages per week for men. 15. Individuals who have clinically significant following severe illness 16. Females who are pregnant/planning to be pregnant or lactating or taking any oralcontraceptives. 17. Any condition that could, in the opinion of the investigator, preclude the individual'sability to successfully and safely complete the study or that may confound studyoutcomes

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Nand Hospital Vadodara Gujarat
Lifeline Clinicand Diagnostics Nashik Maharashtra
AMF MorayaMultispecialityHospital Pune Maharashtra
ENT and VertigoClinic Pune Maharashtra
Madhumeh Clinic New Delhi National Capital Territory of Delhi
Janta Hospital &MaternityCentre Varanasi Uttar Pradesh
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07033754 on ClinicalTrials.gov ↗ ← All trials in India